These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8899574)

  • 1. Health and economic implications of a work-site smoking-cessation program: a simulation analysis.
    Warner KE; Smith RJ; Smith DG; Fries BE
    J Occup Environ Med; 1996 Oct; 38(10):981-92. PubMed ID: 8899574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Work-site health promotion: an economic model.
    Patton JP
    J Occup Med; 1991 Aug; 33(8):868-73. PubMed ID: 1941281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating the short-term clinical and economic benefits of smoking cessation: do we have it right?
    Menzin J; Lines LM; Marton J
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):257-64. PubMed ID: 19527098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic Evaluation of Combining Pharmaco- and Behavioral Therapies for Smoking Cessation in an Occupational Medicine Setting.
    Rejas-Gutiérrez J; López-Ibáñez de Aldecoa A; Casasola M; Varela P; Quesada S; Olive V; Arriaza E
    J Occup Environ Med; 2019 Apr; 61(4):318-327. PubMed ID: 30688765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanding health insurance coverage for smoking cessation treatments: experience of the Pacific Business Group on Health.
    Harris JR; Schauffler HH; Milstein A; Powers P; Hopkins DP
    Am J Health Promot; 2001; 15(5):350-6. PubMed ID: 11502016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling the impact of enhanced depression treatment on workplace functioning and costs: a cost-benefit approach.
    Lo Sasso AT; Rost K; Beck A
    Med Care; 2006 Apr; 44(4):352-8. PubMed ID: 16565636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.
    Athanasakis K; Igoumenidis M; Karampli E; Vitsou E; Sykara G; Kyriopoulos J
    Clin Ther; 2012 Aug; 34(8):1803-14. PubMed ID: 22818870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corporate smoking cessation on Long Island.
    Mulligan P
    Health Promot Pract; 2010 Mar; 11(2):182-7. PubMed ID: 18480319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating smoking control policies into employee benefits: a survey of large California corporations.
    Schauffler HH
    Am J Public Health; 1993 Sep; 83(9):1226-30. PubMed ID: 8362996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impacts of a smoking cessation benefit among employed populations.
    Halpern MT; Dirani R; Schmier JK
    J Occup Environ Med; 2007 Jan; 49(1):11-21. PubMed ID: 17215709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating a collaborative smoking cessation intervention in primary care (ENTER): study protocol for a cluster-randomized controlled trial.
    Härter M; Bartsch AL; Egger N; König HH; Kriston L; Schulz H; Tiemann M; Brütt AL; Buchholz A
    Trials; 2015 Oct; 16():447. PubMed ID: 26452466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs of employee smoking in the workplace in Scotland.
    Parrott S; Godfrey C; Raw M
    Tob Control; 2000 Jun; 9(2):187-92. PubMed ID: 10841855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Varenicline as compared to bupropion in smoking-cessation therapy--cost-utility results for Sweden 2003.
    Bolin K; Mörk AC; Willers S; Lindgren B
    Respir Med; 2008 May; 102(5):699-710. PubMed ID: 18289839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of treating nicotine dependence: the Mayo Clinic experience.
    Croghan IT; Offord KP; Evans RW; Schmidt S; Gomez-Dahl LC; Schroeder DR; Patten CA; Hurt RD
    Mayo Clin Proc; 1997 Oct; 72(10):917-24. PubMed ID: 9379693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Value of a Well-Being Improvement Strategy: Longitudinal Success across Subjective and Objective Measures Observed in a Firm Adopting a Consumer-Driven Health Plan.
    Guo X; Coberley C; Pope JE; Wells A
    J Occup Environ Med; 2015 Oct; 57(10):1055-62. PubMed ID: 26461860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of intensive smoking cessation therapy among patients with small abdominal aortic aneurysms.
    Mani K; Wanhainen A; Lundkvist J; Lindström D
    J Vasc Surg; 2011 Sep; 54(3):628-36. PubMed ID: 21620630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands.
    Hoogendoorn M; Welsing P; Rutten-van Mölken MP
    Curr Med Res Opin; 2008 Jan; 24(1):51-61. PubMed ID: 18021492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cost-benefit analysis of a smoking cessation program.
    Weiss SJ; Jurs S; Lesage JP; Iverson DC
    Eval Program Plann; 1984; 7(4):337-46. PubMed ID: 10311098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluations of smoking cessation and relapse prevention programs for pregnant women: a systematic review.
    Ruger JP; Emmons KM
    Value Health; 2008; 11(2):180-90. PubMed ID: 17854435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The long-term cost-effectiveness of varenicline (12-week standard course and 12 + 12-week extended course) vs. other smoking cessation strategies in Canada.
    von Wartburg M; Raymond V; Paradis PE
    Int J Clin Pract; 2014 May; 68(5):639-46. PubMed ID: 24472120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.